Menu
CinSano Pharma
Motivation: Cancer is the #1 cause of death worldwide [1], with solid tumors representing approximately 90% of adult human cancers, and the need for novel therapeutics targeting oncogenes are in demand now more than ever.
Lead Program(s): CIN-108 is a pre-clinical, small molecule that inhibits defective in cullin neddylation 1 (DCN1) from binding in the pocket where it is necessary to promote neddylation. CIN-108 has the potential to significantly interfere with the progression of cancers, including multiple solid tumors.
Pre-Clinical
Phase 1
Phase 2
Phase 3
Sources:
[1] Cancer (who.int)
